Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Kobayashi N, Hashimoto H, Kamimaki C, Nagasawa R, Tanaka K, Kubo S, Katakura S, Chen H, Hirama N, Ushio R, Aoki A, Nakashima K, Teranishi S, Manabe S, Watanabe H, Horita N, Watanabe K, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T.
Kobayashi N, et al. Among authors: nagasawa r.
Thorac Cancer. 2020 Aug;11(8):2125-2129. doi: 10.1111/1759-7714.13503. Epub 2020 Jun 3.
Thorac Cancer. 2020.
PMID: 32495514
Free PMC article.
Clinical Trial.